Patients must have measurable disease, which includes lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  cm with conventional techniques or as >=  cm with spiral computed tomography (CT) scan
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral CT scan within  weeks of treatment start
Participants are required to have measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] version .), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral computed tomography (CT) scan
PART II: participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patient with measurable tumor lesions with longest diameter ?  mm using conventional techniques or ?  mm with spiral CT scan according to RECIST .
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral computed tomography (CT) scan
PHASE II INCLUSION CRITERIA: Patients must have measurable disease by RECIST criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral CT scan
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: MTD expansion and part II: Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan; CT must be performed within  days of registration
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral computed tomography (CT) scan
Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with CT scan; patients must have at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) and a separate lesion amenable to biopsy
Presence of measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with CT scan
ARM  - A: Presence of measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with CT scan
Patients must have measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  cm with conventional techniques or as >=  cm with spiral CT scan
COHORT II: Measurable disease within the head and neck region, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with neck computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan for the evaluation of measurable disease (Response Evaluation Criteria in Solid Tumors version . [RECIST v.])
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm
Patients must have measurable disease as defined by the RECIST criteria as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ? mm with conventional techniques on either CT or MRI; marker (CA- or CEA) elevation alone is insufficient for\r\nentry
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of  mm by CT scan
Histologically or cytologically confirmed, measurable (defined as those that could be accurately measured in a least  dimension with a longest diameter ? mm using conventional techniques or ? mm with spiral computed tomography scan) or evaluable solid malignancy (with the exception of primary central nervous system [CNS] tumors) per RECIST .. Scans performed within  month of starting study drug will be accepted.
Patients must have radiographically measurable disease defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral computed tomography (CT) scan; lesions in previously irradiated anatomic areas (external beam radiation) cannot be considered target lesions unless there has been documented growth of those lesions after radiotherapy
Patients must have at least one measurable site of disease, defined as a lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) and measures >=  mm with conventional techniques or >=  mm with more sensitive techniques such as magnetic resonance imaging (MRI) or spiral computerized tomography (CT) scan. If the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation.
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with spiral computed tomography (CT) scan
Patient must have measurable disease defined as a lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) and measures >=  mm with conventional techniques or >=  mm with more sensitive techniques such as magnetic resonance imaging (MRI) or spiral computed tomography (CT) scan
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have at least one measurable site of disease, defined as a lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) and measures >=  mm with conventional techniques or >= mm with more sensitive techniques such as magnetic resonance imaging (MRI) or spiral computed tomography (CT) scan; if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan; as well, patients must have primary tumor able to be visualized on ultrasound and amenable to direct injection
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as > mm with CT scan.
Patients must have measurable disease (lesion in previously irradiated field could be considered as measurable if progressive at inclusion) defined as per RECIST v. with at least one lesion that can be measured in at least one dimension (longest diameter to be recorded) as >=  mm with spiral computed tomography (CT) scan
Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) by ultrasound or mammogram
Must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded as >  mm with conventional techniques or >  mm with spiral computed tomography [CT] scanning)
Patient must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan/MRI
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral CT scan
Evidence of measurable disease per RECIST .. Measurable disease is defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with computed tomography (CT) scan
Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with computed tomography (CT) scan or magnetic resonance imaging (MRI)
TUMOR BIOPSY SEQUENCING: Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
TREATMENT: Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral CT scan
Patients must have measurable disease with at least one lesion whose longest diameter can be accurately measured as >= . cm with conventional techniques or as >= . cm with spiral computed topography (CT); if spiral CT is used, it must be used for both pre- and post- treatment tumor assessments
Have measurable (defined as at least one lesion that can be accurately measured in at least one dimension [longest diameter to be recorded]) minimum lesion size of >=  cm on conventional measurement techniques or >=  cm on spiral computed tomography (CT) scan
Measurable metastatic tumor as defined by standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria; lesions must be accurately measured in at least one dimensions with the longest diameter >=  mm; with spiral computed tomography (CT) scan, lesion must be >=  mm in at least one dimension
Have measurable lesion, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded), with minimum lesion size >=  cm on conventional measurement techniques or >=  cm on spiral computed tomography (CT) scan
Measurable disease*: At least one lesion that can be accurately measured in at least one dimension ?  mm with conventional imaging techniques or ?  mm with spiral CT or MRI or
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral computed tomography (CT) scan
Patients must have measurable disease as defined by the RECIST criteria as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= mm with conventional techniques on either CT of MRI; marker (CEA) elevation alone is insufficient for entry
All patients must have measurable disease. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ? mm with conventional techniques or as ?mm with spiral CT scan.
Patients must have at  measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) ., defined as least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques, or as >  mm with spiral computed tomography (CT) scan, and that is accessible for biopsy
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral computed tomography (CT) scan; tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral computed tomography (CT) scan
Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with computed tomography (CT) scan; patients with biopsy-proven metastatic disease that do not meet criteria for measurable disease may be eligible at the discretion of the principal investigator
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  times the slice width with spiral CT scan (i.e.  mm if the CT slice width is  mm,  mm if the CT slice width is  mm)
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography [CT] scan; tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented
For the dose-escalation component of the study, participants are required to have only evaluable disease; for the RPD cohort, participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease within  weeks prior to registration by Response Evaluation Criteria in Solid Tumors (RECIST) ., defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Presence of measurable disease defined as >=  lesion whose longest diameter can be accurately measured as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT)
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Evidence of measurable disease per RECIST .; measurable disease is defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  cm with conventional techniques or as >=  cm with spiral computed tomography (CT) scan
Patients may have measurable or evaluable disease\r\n* Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral CT scan\r\n* Evaluable disease is disease that does not meet the criteria for measurable disease; examples would include patients with effusions or bone-only disease
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ? mm with spiral CT scan
Radiologically measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan; measurable lymph nodes are required to be >=  mm in size (short axis diameter)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria; measureable disease: the presence of at least one measurable lesion; measurable lesions: lesions that can be accurately measured in at least one dimension with the longest diameter >=  mm using conventional techniques or >=  mm using spiral computed tomography (CT) scans
Patients with solid tumors (non-small cell lung cancer, head and neck cancer, urothelial transitional cell carcinoma, and breast cancer) must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan; patients with the above tumor types whose disease is limited to the skin are eligible at the discretion of the principal investigator (PI) and must have a physical exam with documentation of skin lesion(s) by color photography, including a ruler to estimate the size of the lesion(s)
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded)
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with computed tomography (CT) scan; indicator lesions must not have been previously treated with surgery, radiation therapy or radiofrequency ablation unless there is documented progression after therapy
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral computed tomography (CT) scan; target lesions cannot be selected within previously irradiated areas, if not newly arising or clearly progressing after irradiation as proven by repeat scanning
Patients must have shown unequivocal evidence for tumor recurrence or progression and should have at least one indicator lesion, that can be measured in one dimension as >/=mm with conventional techniques (CT, MRI, X-ray) or >/=mm with spiral CT scan.
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan; participants with resectable disease must have a single tumor (with no satellite lesions) with a total diameter or longest dimension of =<  cm; patients with unresectable disease must have a total tumor diameter of <  cm and =<  lesions; satellite lesions defined as lesions =<  cm from the dominant lesion are permitted for participants with unresectable disease
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with computed tomography (CT) scan or clinically (must be measurable with calipers) according to RECIST version .
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan
Must have measurable disease (i.e. with at least one measurable lesion, per Response Evaluation Criteria In Solid Tumors [RECIST]); a measurable lesion is defined as a lesion that can be accurately measured in at least one dimension with the longest diameter >=  mm using conventional techniques or >=  mm with spiral computed tomography (CT) scan; Note: subjects should be excluded if all baseline measurable lesions are within previously irradiated areas; subjects participating in the exploratory analysis shall not have the biopsied lesion(s) as the only sites of measurable disease
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm with conventional techniques or as >  mm with spiral computed tomography (CT) scan
At least one target tumor lesion that has not been irradiated within the past three months and that can accurately be measured by magnetic resonance imaging (MRI) or computed tomography (CT) in at least one dimension (longest diameter to be recorded) as greater than or equal to  mm with conventional techniques or as greater than or equal to  mm with spiral CT.
For phase II, pathologically confirmed breast cancer, measurable disease, no prior chemotherapy treatments for recurrent or metastatic breast cancer; measurable disease is defined as least one lesion that can be accurately measured in at least one dimension as >=  mm by conventional techniques, or as >=  mm by spiral computed tomography (CT) scan
Measurable or evaluable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST, version .) criteria, i.e. lesions that can be accurately measured in at least one dimension with the longest diameter >=  mm using conventional techniques or >=  mm using spiral computed tomography (CT) scan
Patients must have measurable metastases to the brain, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  mm in the brain MRI/CT scan
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm
Patients must have measureable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with conventional techniques (computed tomography [CT], magnetic resonance [MR] or PET); lesions in the previously irradiated area can be considered as measureable lesions as long as there has been an increase of at least  mm when compared to measurements obtained after completion of radiation
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with MRI
Participants must have measurable disease with at least one lesion that can be accurately measured in longest dimension as >  cm with conventional imaging techniques or >  cm with a spiral computed tomography (CT) scan per Response Evaluation Criteria in Solid Tumors version . (RECIST v.)
